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Reviewer #1: Review of JNI-D-15-00061 
 
In this manuscript, the authors present compelling evidence that there 
is a potential association between CXCL13, IgM and MS diagnosis in a 
fairly large cohort (n=120) CIS patients. I have some concerns that 
should be addressed: 
 
1. In section 3.1, the authors note that 86% of the patients were 
diagnosed with MS according to the McDonald criteria, while 45% of the 
patients were diagnosed with MS by the end of the follow-up period.  
These two percentages should be combined with the percentage that did 
not convert so that all three percentages add up to 100%. It is very 
confusing in this context. 
Response 
The paragraph in section 3.1 has been modified as follows: 
“By the end of the follow-up period (mean: 41 ± 18 months, median: 40 months; range: 4-72), 94 (86%) 
patients were diagnosed with MS. Of these, 49 (45%) patients had experienced a relapse (diagnosis of CDMS), 
while in 45 patients (41%) patients, MS diagnosis was established based on MRI criteria of DIS and DIT, in 
accordance with the 2010 McDonald’s criteria (Polman et al., 2011).” 
To avoid confusion, table 1 has also been modified: we eliminated data on patients in whom the initial MS 
diagnosis was based solely on MRI criteria, since some of those patients went on to have a relapse, leading to 
an overlap in the percentages of patients with a diagnosis based on MRI criteria and of patients diagnosed with 
CDMS. 
 
2. In relation to point 1, Table 1 should also include the denominator 
for each percentage calculation rather than just the "n".  
Response 
The denominator has been added for each percentage calculation. 
 
3. I am not convinced that the specificity/sensitivity calculations 
presented in Section 3.3 are all that impressive as they do not 
represent an improvement from current measurements. This section 
should be taken out with the understanding that the paper continues to 
have strong biological implications without it. 
Response 
We eliminated the paragraph on the specificity/sensitivity calculations for the different CXCL13 cut-off values 
and the corresponding Table 2. 
 
4. The authors should generate a scatter bar plot showing the 
concentrations of CXCL13 in the CSF of CIS patients who convert vs 
those who do not. Presumably, the CXCL13 levels in the CSF of CIS 
patients who convert should be statistically higher than in those 
patients who did not—or in those patients who converted later in the 
study. 
Response 
Response to Reviewers
We have added a dotplot (Figure 1) showing CSF CXCL13 values (and median values) in those patients who 
converted to MS versus those who did not, and indicating p-value for comparison between the medians of the 
two groups.     
  
5. CXCL13 is important for attracting B and T cells, rather than ALL 
lymphocytes (as is the case with CXCL12). Did the authors perform 
regressions of CXCL13 levels with B cell numbers or T cell numbers in 
the CSF? This would be more informative. At the very least, the 
authors should discuss how total CSF lymphocyte numbers (if that is 
what was actually measured rather than ALL CSF cells as there are 
others besides lymphocytes) may not be an accurate reflection of the 
impact of CXCL13 on CSF lympyocyte migration. The authors might also 
demonstrate that a more generalized chemokine (such as CXCL12) does 
not correlate with CSF lymphocyte numbers or total CSF cells. 
Response 
Our laboratory measures the number of leukocytes/µl and not the number of lymphocytes (although these were 
the prevalent type of cell at visual inspection). We could, therefore, unfortunately, not specifically discuss the 
impact on CXCL13 on CSF lymphocyte migration, nor could we regress CXCL13 levels with B or T cell numbers. 
 
6. A detailed method of how cell count was calculated must be included 
as this set of data is central to the overall theme of the paper. 
Response 
We have added the following paragraph in section 2.2: 
“CSF cell count was carried out within one hour from sampling as follows: test tube containing CSF was gently 
agitated in order to resuspend cells; CSF was incubated with Turk's solution (mixture of acetic acid and gentian 
violet) (1:2) for ten minutes to lyse erythrocytes and to stain leukocytes; cells were counted using Nageottes’s 
or Fuchs-Rosenthal chamber.”  
  
  
7. Minor point: the use of "have been shown/has been shown/shown 
to be" is excessive. These should be removed. Example: In MS 
patients, elevated CSF CXCL13 levels have been shown to correlate with 
CSF cell count…" should be "In MS patients, elevated CSF 
CXCL13 levels correlated with CSF cell count…" 
Response 
We have followed your advice and corrected the manuscript accordingly. 
 
8. Minor point: highlights point 3 regarding predictive value of 
CXCL13 levels in CSF should be removed. 
 
Response 
It has been removed. 
 
 
Reviewer #2: This interesting manuscript confirms i) the presence of 
higher levels of the chemokine CXCL13 in the CSF of patients with MS, 
and ii) a correlation between the higher levels of CSF CXCL13 and the 
presence of IgM oligoclonal bands. Furthermore, the results show that 
CSF CXCL13 levels of >15.4pg/ml show a high positive predictive 
value for conversion to MS in patients presenting with a clinically 
isolated syndrome, and for a relapse within 1 year of onset. These 
findings suggest that CSF CXCL13 levels could be used as an additional 
tool for predicting patients who might have a more severe clinical 
course. 
 
There are just a couple of minor points that could be addressed: 
1. Page 5, last line of first paragraph - "used" rather than 
"uses" 
Response 
It has been corrected. 
 
2. Page 5, last line in Methods section - "Data were 
analyzed" rather than "Data was analyzed" 
Response 
It has been corrected. 
 
3. Section 3.2 CXCL13 values - it would be useful to have a graph 
showing these results, just so that the reader can get more of a feel 
for the distribution of the data, as it's is not clear whether all 
of the values are reported as means, or whether median values are used 
in some cases. 
Response 
Figure 1 has been added to show distribution of CSF CXCL13 values in those CIS patients who have converted 
to MS and in those who have not. In section 3.2 we have specified whether numbers refer to mean or to 
median values. 
 
4. Figure 1 - The X-axis labels showing "1-specificity" are 
awkward; it would be better to have the X axis labels showing the 
specificity (i.e. starting at 1 at the left side of the axis and going 
down to 0 on the right hand side). 
 
Response 
The figure (which has now become Figure 2) has been modified according to suggestions. 
 
Reviewer #3: The authors have analyzed CSF CXCL13 levels in samples 
from 110 patients with clinically isolated syndrome (CIS). Their 
results confirm previous studies demonstrating a correlation of CSF 
CXCL13 levels with CSF cell count, total protein, IgG Index and with 
the presence of CSF IgG and IgM oligoclonal bands. CSF CXCL13 levels 
are higher in patients who had a clinical relapse within one year from 
onset thus confirming a predictive role of CSF CXL13 levels for the 
conversion to MS after a CIS. The study is well performed and is in 
good agreement with previously published data. 
1) I have, however, one major concern and recommendation for improvement: 
the ROC curves shown in figure 2 are not really convincing due to the 
low area under the curve and the detailed statistical analysis 
(p-values) is missing and must be included.  
Response 
If I have understood your comment correctly, the p-value (that tests the null hypothesis that the area under 
the curve=0.50) is equal to 0.0004 for a MS diagnosis within one year and to 0.017 for a CDMS diagnosis 
within one year (Wilcoxon rank-sum test). This information has been added to the legend of Figure 2. We have 
also added the 95% confidence intervals for the area under the curves (AUC) in section 3.3: AUC for a MS 
diagnosis within one year=71% (CI95%:60-82); AUC for a CDMS diagnosis within one year=64% (CI95%:54-
75).  
  
2) In addition I recommend 
that the authors show a table with the number of patients who 
converted to MS according to revised the McDonald's criteria. This 
table should contain all demographic, MRI and CSF data (CXL13 levels 
and other CSF data) and a statistical analysis using binary logistic 
regression analysis, which will inform the reader on the best 
predictor. 
Response 
We have added the requested information to Table 3. 
  
3) Similarly, the cox regression analysis could not only be 
calculated using CXCL13 cut-off, but also with the CSF CXCL13 raw 
values. 
 
Response 
Cox analysis was carried out on raw CXCL13 values which significantly increased the risk of an MS (but not of a 
CDMS) diagnosis throughout follow-up, although the statistical significance was not confirmed at multivariate 
analysis. This information has been added in section 3.5. 
 
4) Minor points: - Figure 2 (Correlations between CSF CXCL13 levels and CSF cell count 
Legend: R= 0,6; p<0,0001) is not necessary and should be omitted. 
Response 
It has been omitted. 
 
5)- How high were the inter- and intrassay variations for the CSF CXCL13 
ELISA? 
Response 
The following information was provided by the manufacturer:  
 
 
Intra-Assay Precision Inter-Assay Precision 
Sample 1 2 3 1 2 3 
n 20 20 20 40 40 40 
Mean (pg/ml) 50.2 136 294 54 138 285 
Standard Deviation 2.2 4.5 8 5.1 13.2 24.8 
Coefficient of Variability % 4.3 3.3 2.7 9.4 9.6 8.7 
  
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were 
tested twenty times on one plate to assess intra-assay precision. 
Inter-Assay Precision (Precision between assays) Three samples of known concentration were 
tested in forty separate assays to assess inter-assay precision. 
 
6)- More details on the ethical approval would be appropriate (which 
authority was responsible, number of approval). 
Response 
The Ethics Committee of the province of Modena, Italy, approved the study (protocol nr. 116/09). This 
information has been added in section 2.2.  
 
7)- Did the authors also measure serum CXL13 levels?  
Response 
No, we did not measure serum CXCL13 levels. 
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Cerebrospinal fluid CXCL13 in Clinically Isolated Syndrome patients: association 
with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis 
  
Abstract   
Cerebrospinal fluid (CSF) CXCL13 was shown to correlate with markers of intrathecal 
inflammation and CSF oligoclonal IgM bands (IgMOB) have been associated with a more 
severe Multiple Sclerosis (MS) course.  
We correlated CSF CXCL13 levels with clinical, MRI and CSF parameters, including CSF 
IgMOB, in110 Clinically Isolated Syndrome (CIS) patients. 
CSF CXCL13 levels correlated with CSF cell count, total protein, IgG Index and with the 
presence of CSF IgGOB and IgMOB. 
CSF CXCL13 levels ≥15.4pg/ml showed a good positive predictive value and specificity for 
a MS diagnosis and for a clinical relapse within one year from onset. 
 
1. Introduction 
Increasing evidence on the importance of B lymphocytes in the immunopathogenesis of 
Multiple Sclerosis (MS) has encouraged the evaluation of B cell-associated biomarkers in 
the cerebrospinal fluid (CSF). An important chemokine that directs the migration of B cells 
before they differentiate to antibody-secreting cells is CXCL13 (Meinl et al., 2006). Virtually 
all B cells express the receptor to this chemokine, CXCR5, (Kim et al., 2001), which is also 
transiently induced on T cells upon activation (Langenkamp et al., 2003).  
*Manuscript
Click here to view linked References
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 In MS patients, elevated CSF CXCL13 levels have been shown to correlatecorrelated with 
CSF cell count,  IgG index, presence of oligoclonal IgG bands (IgGOB), number of MRI 
brain lesions and presence of MRI gadolinium-enhancing lesions (Festa et al., 2009; 
Khademi et al., 2011; Krumbholz et al., 2006; Kuenz et al., 2008; Ragheb et al., 2011; 
Sellebjerg et al., 2009; Senel et al., 2014). Furthermore, they were shown to be  
associated with a higher relapse rate and to a higher risk of conversion to MS in Clinically 
Isolated Syndrome (CIS) patients (Brettschneider et al., 2010; Khademi et al., 2011). 
In addition, CSF CXCL13 levels were shown to correlatecorrelated with the number of 
CSF CD5+ B cells and with intrathecal IgM production (Villar et al., 2010). Intrathecal IgM 
synthesis (Mandrioli et al., 2008; Sola et al., 2011; Villar et al., 2003, 2002), and intrathecal 
lipid-specific IgM synthesis (Thangarajh et al., 2008; Villar et al., 2005) have been 
associated with a more aggressive disease course and with an earlier conversion to 
Clinically Definite MS (CDMS) in CIS patients (Boscá et al., 2010; Ferraro et al., 2013).     
Our aim was to correlate CSF CXCL13 levels with clinical, MRI and CSF parameters, 
including CSF oligoclonal IgM bands (IgMOB), in a cohort of CIS patients who were 
followed up for at least two years or until a relapse occurred, and to explore the possible 
role of CXCL13 in predicting a MS/CDMS diagnosis and an “early” MS/CDMS diagnosis, 
defined as a diagnosis or a relapse occurring within one year from onset.  
 
2. Methods and Materials 
2.1 Patient Data collection 
Of all consecutive patients seen at the MS Center of the Nuovo Ospedale Civile 
Sant’Agostino Estense (Modena, Italy) between January 2007 and November 2011, we 
included patients with the following inclusion criteria: patients at their first demyelinating 
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event who performed a spinal tap and a brain MRI scan, and whose CSF and serum 
samples were stored at -80°C in our laboratory within two hours of collection. Patients 
were followed-up for at least two years or until a clinical relapse occurred. Of these, we 
recorded demographical (sex, age at onset), clinical (symptoms at onset, EDSS at onset, 
clinical recovery), MRI (presence and number of brain and spinal cord MRI lesions, 
presence and number of gadolinium-enhancing lesions on MRI, presence of infratentorial 
lesions)  and CSF variables (CSF proteins, cell count, Link’s IgG Index, presence of 
IgGOB), as well as follow-up data including the occurrence of relapses and dissemination 
in space (DIS) and time (DIT) of demyelinating lesions on MRI. 
2.2 Laboratory procedures  
CSF cell count was carried out within one hour from sampling as follows: test tube 
containing CSF was gently agitated in order to resuspend cells; CSF was incubated with 
Turk's solution (mixture of acetic acid and gentian violet) (1:2) for ten minutes to lyse 
erythrocytes and to stain leukocytes; cells were counted using Nageottes’s or Fuchs-
Rosenthal chamber. 
Laboratory CXCL13 determination and IgMOB detection wasprocedures were carried out 
on CSF (and serum samples, in case of IgMOB detection) which, at the time of the 
diagnostic spinal tap, had been centrifuged at 3000 rpm for 10 minutes and stored in 
cryovial tubes at – 80°C within two hours from collection.  
  
2.2.1 CXCL13 determination 
Formatted: Font: Not Italic
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CSF CXCL13 levels were measured using the Human CXCL13/BLC/BCA-1 Quantikine 
ELISA Kit (R&D Systems, Minneapolis, Minnesota, USA), according to the instructions as 
supplied by the manufacturer. The minimal detectable dose (MDD), as reported by the 
manufacturer, is 1.64pg/ml. We used a standard curve ranging from 0 to 500 pg/ml. 
Measurements were performed in duplicates using 50 l undiluted CSF. The optical 
density was determined using a microplate reader (Beckman Coulter DTX 800/880) set for 
dual wavelength analysis to 450/620 nm. 
2.2.2 IgM oligoclonal band detection 
CSF and serum samples were analyzed for the presence of IgMOB by means of agarose 
gel isoelectric focusing (IEF) followed by immunoblotting with polyclonal specific anti-
human IgM antibodies (Dako), according to the method proposed by  Villar et al (Villar et 
al., 2001), with the following modifications: for Agarose IEF gel we used 2 ml of 
Pharmalyte (GE Healthcare), pH 5-8 and 1 ml of Pharmalyte, pH 3-10; the electrode strips 
were soaked with 1 M NaOH and 0,01 M H2SO; ten-microliter paired samples were 
applied on a sample application strip; the PVDF membrane was previously wetted in 
ethanol and then washed in two changes of saline for the total migration time; the 
membrane was incubated with a polyclonal rabbit anti-human IgM (Dako Cytomation) 
diluted 1:500 in 0,1% TWEEN 20 in saline for 30 minutes and then with a polyclonal swine 
anti-rabbit IgG/AP (Dako Cytomation) diluted 1: 500 in 0,1% TWEEN 20 in saline solution 
for 30 minutes. 
The presence of CSF IgMOB (at least two) was blindly assessed by two independent 
neurologists (DF and PS) and by a biologist (RB) in case of discrepancies. 
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At the time of the diagnostic spinal tap patients signed an informed consent permitting the 
storage and the use for research purposes of their serum and CSF samples. The Ethics 
Committee of the province of Modena, Italy, approved the study (protocol nr. 116/09). 
Ethics committee approval was obtained for this study.  
2.3 Statistical methods  
 
We calculated absolute frequencies and percentages for categorical variables and mean ± 
standard deviation and median for continuous variables. Correlations between CXCL13 
levels and collected variables were analyzed using Spearman’s rank test and Wilcoxon’s 
rank sum test for categorical variables. Mann-Whitney’s test and equalitu of medians test   
was used to explore differences between groups. Wilcoxon’s rank sum test was used to 
explore the null hypothesis that the AUC=0.5. 
Receiver Operating Characteristics (ROC) analysis, calculating the area under the curve 
(AUC), was used to examine the accuracy of CXCL13 values in differentiating patients 
who remained with a CIS diagnosis from those who acquired a diagnosis of MS/CDMS. 
Youden Index was useds to determine the best cut-off values 
Sensitivity was calculated as (true-positive/[true-positive + false-negative]), specificity was 
calculated as (true-negative/[true-negative + false-positive]). The positive predictive value 
(PPV) was calculated as (true-positive/[true-positive + false-positive]), and the negative 
predictive value (NPV) as (true-negative/[true-negative + false-negative]).   
The impact of baseline characteristics on the risk of an early diagnosis of MS/CDMS (i.e. 
within one year) was analyzed using logistic regression and the risk of a diagnosis of 
MS/CDMS throughout the follow-up period was analyzed using survival analysis (Kaplan-
Formatted: Font: Not Italic
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Meier survival curves followed by Log-rank test). The impact of the recorded variables on 
the risk of a MS/CDMS diagnosis was analyzed using a univariate and multivariate Cox 
analysis.  
P-values below 0.05 were considered significant. Data wereas analyzed using STATA 11 
(StataCorp, Texas, USA). 
3. Results 
3.1 Patients 
Of 120 evaluated CIS patients, five were excluded from the analysis because spinal tap 
was not carried out (due to patients’ refusal or to concomitant anticoagulant therapy in one 
case), two because baseline MRI was not carried out (due to claustrophobia) and three 
because the spinal tap had been carried out elsewhere. One-hundred and ten patients 
were included in the study. Patients’ characteristics are shown in Table 1. Conversion to 
CDMS was defined by the occurrence of new or worsening neurological symptoms lasting 
at least 24 hours, associated with at least a one-point increase in an EDSS functional 
score, not accompanied by fever or infection. Baseline MRI was carried out after a mean 
period of 24 days from onset (range 0-8 months). Follow-up MRI was carried out after a 
mean period of 4 months (range 1-12). By the end of the follow-up period (mean: 41 ± 18 
months, median: 40 months; range: 4-72), A diagnosis of MS was established in 94  (86%) 
patients were diagnosed with MS. Of these, 49 (45%) patients had experienced a relapse 
(diagnosis of CDMS), while in 45 patients (41%) patients, MS diagnosis was established 
based on MRI criteria of DIS and DIT, according toin accordance with the 2010 
McDonald’s criteria (Polman et al., 2011). while a diagnosis of CDMS was established in 
49 (45%) patients by the end of the follow-up period (mean: 41 ± 18 months, median: 40 
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months; range: 4-72).  An early diagnosis, i.e. within one year, occurred in 74 (67%) and 
an early relapse in 34 (31%) patients.   
3.2 CXCL13 values 
Mean CSF CXCL13 levels were 31pg/ml ± 55 (range: 0-357), median value was 
13.5pg/ml. Mean CXCL13 levels were significantly higher in patients who acquired a MS 
diagnosis in accordance with McDonald’s criteria throughout the follow-up period versus 
those who did not (35.8pg/ml versus 2.5pg/ml; ; p<0.0001). Figure 1 shows a dotplot of 
CSF CXCL13 values in the two groups of patients and indicates median values. ,Mean 
CXCL13 levels were also significantly higher in patients with CSF IgGOB (34.8pg/ml 
versus 24.9pg/ml; p<0.0001), in patients with IgMOB (44.7pg/ml versus 23.7pg/ml ; 
p=0.009) and in those with an increased CSF cell count (49.9pg/ml versus 16.3pg/ml; 
p<0.0001).  
3.3 CXCL13 diagnostic accuracy 
ROC analyses were carried out for CSF CXCL13 levels in relation to an early MS/CDMS 
diagnosis (within one year from onset) (Figures 1a and 1b, respectively) and also in 
relation to the occurrence of a diagnosis of CDMS throughout the follow-up period (figure 
not shown). 
For a MS diagnosis within one year, the optimal CSF CXCL13 cut-off value was 8.7pg/ml, 
which yielded a sensitivity of 66.2% and a specificity of 63.9%. The area under the curve 
(AUC) was 71% (95% confidence interval: 60-82) (Figure 21a). For a CDMS diagnosis 
within one year, the cut-off value of 8.7pg/ml yielded a sensitivity of 74% and a specificity 
of 51.3% (Figure 21b), with an AUC of 64% (95% confidence interval: 54-75), while the 
8 
 
 
 
optimal cut-off of 15.4pg/ml increased its specificity (sensitivity: 64.7%; specificity: 63.1%) 
(Figure 1b). Similarly, for a CDMS diagnosis throughout the follow-up period (figure not 
shown), the cut-off of 15,4pg/ml revealed a sensitivity of 61.2% and a specificity of 67.1%, 
with an AUC of 64%. Figure 21 displays the ROC analysis for MS/CDMS diagnosis within 
one year, showing two different cut-off values (8.7pg/ml and 15.4pg/ml). 
Table 2 shows sensitivity, specificity, PPV and NPV for the two different CSF CXCL13 cut-
off values (8.7 and 15.4pg/ml), for the presence of CSF-restricted IgGOB, and for the 
presence of at least one lesion on T2-weighted images on baseline MRI scan in relation to 
an early MS/CDMS diagnosis and to a CDMS diagnosis throughout the follow-up period.    
We chose to further discuss the cut-off value of 15.4pg/ml since it combines the best 
sensibility/specificity values for an early CDMS diagnosis. 
3.4 CXCL13 correlation analyses 
CSF CXCL13 values correlated with CSF cell count (R= 0.6; p<0.0001) (Figure 32), CSF 
total protein (R=0.5; p<0.0001), CSF IgG Index (R=0.3; p=0.008), (figures not shown) and 
with the presence of CSF IgGOB (p<0.0001) and IgMOB (p=0.009).  
3.5 Survival analysis 
Of all the collected clinical, neuroradiological and immunological variables, only an 
elevated CSF cell count (HR: 1.04; 95%CI:1.01-1.07; p=0.006), a positive baseline MRI 
(defined by the presence of at least one lesion on T2-weighted images) (HR:5; 95%CI: 
1.2-21.3; p=0.029), a positive baseline spinal cord MRI (HR:1.7; 95%CI: 1.1-2.7; p=0.017)  
and CSF CXCL13 levels≥15.4pg/ml increased the risk of a MS diagnosis (HR: 3; 95%CI: 
1.8-4.9; p<0.001). Cox analysis using raw CXCL13 values also yielded significant results 
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(HR:1; 95%CI: 1-1.007; p=0.012), although significance was lost at multivariate analysis.    
When combined in a multivariate model, only a positive baseline brain MRI (p=0.01) and 
high CSF CXCL13 levels > 15.4pg/ml (p<0.001) maintained a statistical significance.   
The risk of a CDMS diagnosis throughout the follow-up period at survival analysis was only 
increased by the presence of CSF-restricted IgGOB (HR:7.3; 95%CI: 1-53.1; p=0.049) and 
by CXCL13 levels≥15.4pg/ml (HR:2.9; 95%CI: 1.2-3.9; p=0.007). In a multivariate Cox 
model, only elevation of CXCL13 values maintained a statistical significance (p=0.045 for 
levels greater than 15.4pg/ml).    
Figure 43 shows Kaplan Meier relapse-free survival in patients with CSF CXCL13 levels 
greater or lower than 15.4pg/ml. The log-rank test revealed a p-value of 0.005. Similar 
curves (data not shown) and an even lower p-value (<0.001) was obtained for diagnosis-
free survival in patients with CXCL13 levels above or below the cut-off of 15.4pg/ml.   
3.6 Logistic regression: risk factors for an early MS/CDMS diagnosis 
Logistic regression analysis showed that, amongst other clinical, CSF and MRI variables 
CSF CXCL13 levels of at least 15.4pg/ml increased the risk of an early diagnosis (OR: 3.6; 
95%CI:1.5-8.5; p=0.005) (Table 23). Similar results were obtained by analyzing the risk of 
an early relapse (OR: 2.7; 95%CI: 1,2-6.4; p=0.017) for CXCL13 levels  ≥15.4pg/ml.     
Discussion 
The main findings of this study are that elevated CSF CXCL13 levels in CIS patients are 
associated with other CNS inflammatory markers (cell count, total protein, Link’s Index, 
CSF-restricted IgGOB) and negative prognostic markers (CSF-restricted IgMOB) and that 
they increase the risk of a MS/CDMS diagnosis and of an early MS/CDMS diagnosis, i.e., 
within one year from onset.  
10 
 
 
 
Our results confirm previously published data by Khademi et al (Khademi et al., 2011), 
reporting that CSF CXCL13 levels were higher in 31 CIS patients who converted to CDMS 
within two years from their first episode, compared to 48 CIS patients who did not. 
Moreover, within the group of patients who converted to CDMS, higher CXCL13 levels 
exhibited a trend to an earlier conversion. Similarly, Brettschneider et al (Brettschneider et 
al., 2010) determined CSF CXCL13 values in a prospective 2-year study, including 91 CIS 
patients and 30 controls. These authors found that CSF CXCL13 was significantly higher 
in patients who converted to CDMS (45/91, 49.5%) compared to those who remained CIS 
and controls (p<0.001). They also found CXCL13 levels greater than 7.7pg/ml (optimal 
cut-off value obtained by applying the Youden Index) to have a sensitivity of 62% and a 
specificity of 76% for a MS diagnosis, and to have the best PPV (70%) of all single 
parameters investigated, being superior to Barkhof’s criteria, IgGOB and MRZR (positive 
polyspecific intrathecal B cell response against measles, rubella and varicella zoster virus). 
In the present study, we found a similar optimal cut-off value (8.7pg/ml), able to 
differentiate those patients who remained CIS from those who converted to MS within one 
year (see Figure 21 and Table 2). However, increasing the cut-off value to 15.4pg/ml 
notably increased its specificity in identifying patients at risk of an early conversion to 
MS/CDMS. Compared to other known diagnostic/prognostic factors, such as the presence 
of CSF-restricted IgGOB and to MRI parameters, elevated CSF CXCL13 levels show a 
lower sensitivity and a lower NPV but a much higher specificity (IgGOB: 31%, MRI: 36%, 
CXCL: 75%) and the highest PPV (IgGOB: 75%, MRI: 67%, CXCL: 81%) for a MS 
diagnosis within one year from onset.  
Results obtained this far, therefore, imply that elevated CSF CXCL13 should highly 
encourage an early preventive treatment while a negative result is less informative. 
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Confirmatory studies are necessary to determine the optimal CSF CXCL13 cut-off value. 
Elevated CSF CXCL13 levels do not only increase the risk of a MS diagnosis and of a 
clinical relapse at survival analysis, but they also predict an early MS diagnosis (i.e. within 
one year) and an early clinical relapse at logistic regression analysis, alongside other 
clinical, CSF and MRI parameters (see table 23 for variables associated with an early MS 
diagnosis). In particular, the presence of CSF IgGOB and of at least one lesion on brain 
MRI, factors which are known to increase the risk of developing MS in CIS patients (Optic 
and Treatment, 2008; Tintoré et al., 2008, 2006), presented the highest OR for a MS 
diagnosis within one year (OR:32 and 21, respectively), followed by positivity of spinal cord 
MRI (OR: 6.8) and CSF CXCL13 levels of at least 15.4pg/ml (OR: 3.6).   
Furthermore, in multivariate survival analysis models on the risk of a MS diagnosis, only 
MRI data and elevated  CSF CXCL13 values > 15.4pg/ml maintained a statistical 
significance while CSFCXCL13 levels alone maintained a statistical significance on the 
risk of a relapse throughout the follow-up period. 
We found an association between CSF CXCL13 levels and the presence of CSF IgMOB. 
23/38 (61%) IgMOB-positive patients showed CSF CXCL13 levels ≥15.4pg/ml (chi-square 
test: p=0.014), and IgMOB-positive patients have significantly higher mean CSF CXCL13 
levels (p=0.009). There is increasing evidence on the association between intrathecal 
IgM/lipid-specific IgM synthesis and a more aggressive disease course (Mandrioli et al., 
2008; Thangarajh et al., 2008; Villar et al., 2005, 2003, 2002). This may be due to its 
multimetameric structure being an efficient complement activator. Complement activation 
can, in turn, cause extensive demyelination and axonal loss (Mead et al., 2002). Villar et al 
(Villar et al., 2010) investigated the immunological mechanisms associated with intrathecal 
12 
 
 
 
IgM production: they found  a close correlation between IgM index and CSF CD5+ B cells, 
which are postulated to be responsible for intrathecal IgM synthesis. Increased CD5+ B 
cells also correlated with CSF CXCL13, which probably induced the CD5+ B cell migration 
into the central nervous system (CNS). Elevated CD5+ expression on B lymphocytes was 
moreover shown to  correlated with MS disease activity, number of gadolinium-enhancing 
lesions on MRI and to be was inversely correlated with disease duration (Seidi et al., 
2002). Our data is in agreement with that of, Villar et al (Villar et al., 2010), who found 
higher CSF CXCL13 levels in patients with intrathecal IgM production, especially during 
relapses, than in patients without intrathecal IgM synthesis.   
In accordance with previous studies (Festa et al., 2009; Khademi et al., 2011; Krumbholz 
et al., 2006; Kuenz et al., 2008; Ragheb et al., 2011; Sellebjerg et al., 2009; Senel et al., 
2014), we found a positive correlation of CXCL13 levels with other markers of CNS 
inflammation, including CSF cell count, total protein, IgG index and CSF IgGOB. An 
elevated CSF cell count has been shownwas found to be associated with short-term 
conversion to MS in CIS (Ferraro et al., 2013; Gout et al., 2011). We could not find a 
correlation with EDSS, as previously reported by Alvarez et al (Alvarez et al., 2013) and 
correlation with number of MRI lesions and number of gadolinium-enhancing lesions did 
not reach statistical significance (p=0.07 and p=0.08, respectively).  
Elevated CSF CXCL13 levels are not specific for MS, since they have been reported in 
other different inflammatory conditions of the CNS, including neuroborreliosis, bacterial 
and viral infections, CNS lymphoma, and neuromyelitis optica (Alvarez et al., 2013). In the 
CNS, CXCL13 is expressed by cells with macrophage morphological features in the 
perivascular, inflammatory lesions, and in scattered parenchymal cells (Krumbholz et al., 
2006). It has been found to be implicated in the pathogenesis of Experimental 
13 
 
 
 
Autoimmune Encephalitis (EAE), as CXCL13-deficient mice exhibited a mild, self-limited 
form of disease (Bagaeva et al., 2006), and intracerebral expression of CXCL13 is 
associated with the development of lymphoid follicle-aggregates in the meninges of mice 
with relapsing EAE (Magliozzi et al., 2004). In MS CXCL13 is produced in actively 
demyelinating MS lesions but not in chronic inactive lesion or in the CSF of controls 
(Krumbholz et al., 2006). CSF CXCL13 levels decrease following treatment with high-dose 
methylprednisolone, natalizumab (Sellebjerg et al., 2009), and rituximab (Piccio et al., 
2010). 
Taken together, data from animal models and from MS populations, showing a relationship 
between CSF CXCL13 levels and disease activity, relapse rate and disability, in addition to 
their reduction in response to treatment with natalizumab or rituximab, suggest an 
important role for CXCL13 in MS pathogenesis. CXCL13 is important for attracting and 
maintaining B and T cells in inflamed CNS lesions and inflammatory CNS can provide a B-
cell-friendly environment which can contribute to the long-term survival of B cells and 
plasmablasts (Corcione et al., 2004).   
CIS patients with elevated CSF CXCL13 levels at onset have a high probability of 
presenting an early diagnosis/clinical relapse. Higher CXCL13 levels have been found to 
correlate with relapse rate in 52 Relapsing-Remitting MS (RRMS) patients who were 
followed-up for 5 years (Khademi et al., 2011). Since a higher relapse rate in the first two 
years (Leray et al., 2010) and a shorter first inter-attack interval seem to predict future 
disability (Scalfari et al., 2010), patients with elevated CSF CXCL13 levels may be at 
higher risk of long-term disability. 
Conclusion 
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CSF CXCL13 levels correlate with markers of CNS inflammation including CSF cells, total 
protein, IgGOB, and with the presence of IgMOB, which have been shown to be 
associated with an earlier conversion to CDMS and with a more aggressive disease 
course. 
Furthermore, we found CXCL13 values ≥15.4pg/ml to have a high PPV and specificity 
(greater than the PPV and specificity of CSF IgGOB and of a positive baseline MRI scan) 
for a MS/CDMS diagnosis and for an early MS/CDMS diagnosis. (i.e. within one year from 
onset). CSF CXCL13 levels could be considered as an additional tool for treatment 
decisions by identifying patients at high risk of an early relapse, who could be encouraged 
to start an early preventive treatment.  
Figure Titles and legends: 
Figure 1 Title: CSF CXCL concentrations in patients who remained CIS (CIS) versus 
those who converted to MS (MS) throughout follow-up 
Horizontal bar indicates median value: 0.1pg/ml (range: 0-14; 25%-75% percentile: 0-0.4) 
(CIS) versus 15.6pg/ml (range: 0-357.7; 25%-75% percentile: 4-38.8) (MSCIS), p=0.003 
Figure 21 Title: Receiver operating characteristic (ROC) curve for CSF CXCL13 levels in 
relation to a MS/CDMS diagnosis within one year from onset.  
Legend: ROC analysis of CSF CXCL13 levels in relation to a MS (Figure 21a) and a 
CDMS (Figure 21b) diagnosis within one year from onset. Two different cut-off values 
(8.7pg/ml and 15.4pg/ml) are shown. P<0.001 for a MS diagnosis within one year and 
p=0.017 for a CDMS diagnosis within one year (null hypothesis: AUC = 0.5). 
Figure 32 Title: Correlations between CSF CXCL13 levels and CSF cell count  
Legend: R= 0,6; p<0,0001  
Figure 34 Title: Time to clinical relapse   
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Legend: Kaplan Meier relapse-free survival in patients with CSF CXCL13 levels greater or 
lower than 15.4pg/ml (Log-rank test: p=0.005). 
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Table 1 Patient characteristics at baseline (nr=110) 
Variable     
Sex  
M, n(%)  
F, n(%)  
Nr/total   
40/110 (36)  
70/110 (64)  
Age at onset , years*  35  ±  10 
Symptoms at onset  
ON**, n(%)  
Sensory, n(%)  
Motor/sensory-motor, n(%)  
Brainstem/cerebellum, n(%)  
Other, n(%)  
 
26/110 (24)  
25/110 (23)  
24/110 (22)  
29/110 (27)  
6/110 (5)  
Spinal onset  
Yes, n(%)  
No, n(%)  
 
39/110 (35)  
71/110 (65)  
EDSS at onset*  2 ±  0.7 
Complete recovery, n(%)  83/110 (75)  
Baseline brain MRI  
Positive (at least one lesion), n(%)  
Negative, n(%)  
 
101/110 (92)  
9/110 (8)  
Baseline brain MRI  
0 lesions, n(%)  
1-2 lesions, n(%)  
3-8 lesions, n(%)  
>9 lesions, n(%) 
 
9/110 (8)  
10/110 (9)  
33/110 (30) 
58/110  (53) 
Baseline brain MRI scan: presence of CE§, n(%)  42/74 (57)  
Tables
  2 
 
Baseline spinal cord MRI  
Positive (at least one lesion), n(%)  
Negative, n(%)  
 
61/74(82)  
13/74(18)  
CSF proteins (g/dl) *(range)  
Link’s IgG index* (range)  
 
41 ± 16 (18-89) 
1.1 ± 0.6 (0.3-4.5) 
Patients with CSF IgGOB, n (%)  98/110 (8990)  
Patients with CSF IgMOB, n (%)  38/110 (35)  
Mean CSF cell count (normal value≤<4) *  
Patients with increased cell count, n (%) 
6.1 ± 7.1 (0-39) 
48/110 (44) 
Diagnosis at onset (MRI with DIS and DIT§§), n(%)  
Diagnosis after follow-up MRI (DIS and DIT§§), n(%)  
Diagnosis of MS within 1 year, n(%) 
Diagnosis of CDMS within 1 year, n(%) 
Diagnosis of MS by end of follow-up period, n(%) 
Diagnosis of CDMS by end of follow-up period, n(%) 
36 (33)   
37 (34)  
74/110 (67) 
34/110 (31) 
94/110 (86) 
49/110 (45) 
* Values expressed as mean ± SD; **ON=optic neuritis; §CE= contrast enhancement;  
§§ DIS and DIT=dissemination in space and dissemination in time, in accordance with McDonald’s 
2010 criteria. 
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Table 23 
Descriptive Assessment of the association between patient baselinebBaseline clinical, MRI 
and CSF characteristics and risk of MS diagnosis at one year (univariate logistic regression 
results). 
and diagnosis of Multiple Sclerosis at one year 
Variable CIS 
(n=36) 
MS 
(n=74) 
OR 95%CI P 
Sex (Male/female)  16/20 24/50 0.6  0.6-1.4  0.221 
Age (years) ± SD 
Age (>30/<=30)  
39±11 
 29/7 
33±9 
 41/33  
0.94 
0.3  
 0.89-0.98 
0.1-0.77  
 0.007 
0.012  
CSF IgGOB (Present/Absent)  25/11 73/1 32.1 3.9-261.5  0.001 
CSF IgMOB (Present/Absent)   15/21 23/51 0.6 0.2-1.4 0.275 
CSF cell count (µl) ± SD 
CSF cell count (Elevated/Normal) 
4±7 
10/26 
7±7 
38/36 
1.1 
2.3 
1-1.17 
1.2-6.4 
 0.06 
0.021 
CSF protein count (mg/dl) ± SD 
CSF protein count (Elevated/Normal) 
40±14 
6/30 
41±17 
19/55 
1 
1.7 
1-10.3 
0.6-4.8 
0.598 
0.294 
CSF CXCL13 levels (>8.7pg/ml/≤8.7pg/ml)  
CSF CXCL13 levels (pg/ml)± SD 
CSF CXCL13 levels (>15.4pg/ml/≤15.4pg/ml) 
 
22 
9/27 
 
35 
40/34 
3.5  
1 
3.6 
1.5-8  
1-1.02 
1.5-8.5 
0.003  
0.253 
0.005 
Recovery (No/Yes) 7/29 20/54  1.5   0.6-4.1   0.388   
Spinal onset (Yes/No)  13/23 26/48 1  0.4-2.2  0.920 
Brain MRI (Pos*/Neg)  28/8 73/1 20.9 2.5-174.4  0.005 
Formatted: Font: Not Italic
Formatted Table
Tables
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Presence of brain CE§ (Yes/No) 15/19 47/25 2.3 1-5.5 0.041 
Spinal cord MRI (Pos*/Neg) (74 patients) 16/9 45/4 6.8  1.8-25.1 0.004 
Infratentorial lesions (Yes/No) 13/23 40/34 2.1 0.9-4.7 0.08 
CIS = patients who remained CIS at one year 
MS = CIS patients who converted to MS within one year 
Statistically significant results in bold. 
* Positive= at least one lesion 
§CE= contrast enhancement 
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